Richard G Stock

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. doi request reprint Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure
    Richard G Stock
    Departments of Radiation Oncology Urology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 110:1257-61. 2012
  2. ncbi request reprint The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 112:E44-50. 2013
  3. doi request reprint PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure
    Eric C Ko
    Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 83:600-7. 2012
  4. doi request reprint Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation
    Richard G Stock
    Department of Radiation Oncology and Urology, Mount Sinai School of Medicine, New York, New York 10025, USA
    J Urol 183:546-50. 2010
  5. doi request reprint Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy
    Richard G Stock
    Departments of Radiation Oncology and Urology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 104:1631-6. 2009
  6. doi request reprint Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai Hospital, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 74:753-8. 2009
  7. doi request reprint Current topics in the treatment of prostate cancer with low-dose-rate brachytherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, Mount Sinai Hospital, 1184 5th Avenue, New York, NY 10029, USA
    Urol Clin North Am 37:83-96, Table of Contents. 2010
  8. doi request reprint Distant and local recurrence in patients with biochemical failure after prostate brachytherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, 1184 5th Avenue, New York, NY 10025, USA
    Brachytherapy 7:217-22. 2008
  9. ncbi request reprint A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 68:1410-6. 2007
  10. doi request reprint Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy
    Alice Y Ho
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 75:16-22. 2009

Collaborators

Detail Information

Publications84

  1. doi request reprint Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure
    Richard G Stock
    Departments of Radiation Oncology Urology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 110:1257-61. 2012
    ..This study provides information on the prognostic significance of primary Gleason pattern in the brachytherapy management of prostate cancer. Study Type - Prognosis (case series) Level of Evidence 4...
  2. ncbi request reprint The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 112:E44-50. 2013
    ..To compare the relative importance of radiation dose escalation vs androgen deprivation therapy (ADT) in the definitive treatment of prostate adenocarcinoma...
  3. doi request reprint PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure
    Eric C Ko
    Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 83:600-7. 2012
    ..5 ng/mL following brachytherapy is associated with decreased PSA failure and/or distant metastasis...
  4. doi request reprint Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation
    Richard G Stock
    Department of Radiation Oncology and Urology, Mount Sinai School of Medicine, New York, New York 10025, USA
    J Urol 183:546-50. 2010
    ..We assessed the impact of androgen suppressive therapy on biochemical failure in patients with intermediate risk prostate cancer treated with brachytherapy and external beam irradiation...
  5. doi request reprint Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy
    Richard G Stock
    Departments of Radiation Oncology and Urology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 104:1631-6. 2009
    ..To assess the outcomes for patients with Gleason score 8-10 prostate cancer treated with brachytherapy, external beam radiotherapy (EBRT) and hormonal therapy (HT)...
  6. doi request reprint Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai Hospital, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 74:753-8. 2009
    ..To analyze the prognosis and outcomes of patients who remain free of biochemical failure during the first 5 years after treatment...
  7. doi request reprint Current topics in the treatment of prostate cancer with low-dose-rate brachytherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, Mount Sinai Hospital, 1184 5th Avenue, New York, NY 10029, USA
    Urol Clin North Am 37:83-96, Table of Contents. 2010
    ..This article focuses on the development of a real-time ultrasound-guided implant technique, the importance of radiation dose, trimodality treatment of high-risk disease, long-term treatment outcomes, and treatment-associated morbidity...
  8. doi request reprint Distant and local recurrence in patients with biochemical failure after prostate brachytherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, 1184 5th Avenue, New York, NY 10025, USA
    Brachytherapy 7:217-22. 2008
    ..To analyze the patterns of failure after the brachytherapy management of localized prostate cancer...
  9. ncbi request reprint A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 68:1410-6. 2007
    ..To examine whether possession of genetic alterations in the ATM (ataxia telangiectasia) gene is associated with rectal bleeding in a dose-dependent and volume-dependent manner...
  10. doi request reprint Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy
    Alice Y Ho
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 75:16-22. 2009
    ..To evaluate the influence of patient- and treatment-related factors on freedom from biochemical failure (FFbF) in patients with intermediate-risk prostate cancer...
  11. doi request reprint Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer
    Ryan J Burri
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Radiat Res 170:49-59. 2008
    ..002). These results suggest that SNPs in the SOD2, XRCC1 and XRCC3 genes are associated with the development of late radiation injury in patients treated with radiation therapy for prostate adenocarcinoma...
  12. ncbi request reprint Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY 10075, USA
    Brachytherapy 9:114-8. 2010
    ..To investigate the morbidity of higher radiation doses in prostate cancer patients...
  13. ncbi request reprint (125)I monotherapy using D90 implant doses of 180 Gy or greater
    Johnny Kao
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 70:96-101. 2008
    ..The purpose of this study was to characterize the oncologic results and toxicity profile of patients treated with (125)I implants using the dose delivered to 90% of the gland from the dose-volume histogram (D90) of greater than 144 Gy...
  14. ncbi request reprint A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer
    Sarah L Kerns
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Urol 190:102-8. 2013
    ..We identified single nucleotide polymorphisms associated with change in the AUA Symptom Score after radiotherapy for prostate cancer...
  15. doi request reprint Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer
    Kevin Forsythe
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 83:630-5. 2012
    ..To measure the benefits of intensity-modulated radiotherapy (IMRT) compared with three-dimensional conformal radiotherapy (3D-CRT) when used in combination with brachytherapy for the treatment of prostate cancer...
  16. doi request reprint Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer
    Ryan J Burri
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York, USA
    Int J Radiat Oncol Biol Phys 77:1315-21. 2010
    ..To evaluate retrospectively the biochemical outcomes of young men treated with low-dose-rate brachytherapy for prostate cancer...
  17. ncbi request reprint TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy
    Christopher A Peters
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 70:752-9. 2008
    ..To investigate whether the presence of single nucleotide polymorphisms (SNPs) located within TGFB1 might be predictive for the development of adverse quality-of-life outcomes in prostate cancer patients treated with radiotherapy...
  18. ncbi request reprint Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation
    Lucille N Lee
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 52:444-52. 2002
    ..To study the impact of hormonal therapy (HTx) on intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation...
  19. ncbi request reprint Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy
    Alice Y Ho
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 69:677-84. 2007
    ..The ATM gene product is a central component of cell cycle regulation and genomic surveillance. We hypothesized that DNA sequence alterations in ATM predict for adverse effects after external beam radiotherapy for early breast cancer...
  20. ncbi request reprint Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 64:527-33. 2006
    ..To analyze the effect of biologically effective dose (BED) values on prostate-specific antigen (PSA) failure and posttreatment biopsy...
  21. ncbi request reprint Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    Urology 69:338-42. 2007
    ..To define the long-term morbidity in patients with prostate cancer who underwent iodine-125 brachytherapy...
  22. doi request reprint Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 73:341-6. 2009
    ..To investigate the biochemical control rates and survival for Gleason score 7-10 prostate cancer patients undergoing permanent prostate brachytherapy as a function of the biologic effective dose (BED)...
  23. ncbi request reprint ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 61:196-202. 2005
    ....
  24. doi request reprint Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 185:495-500. 2011
    ..We describe how treatment factors influence biochemical freedom from failure, local control, freedom from metastasis and cause specific survival in patients treated with prostate brachytherapy...
  25. ncbi request reprint Findings at cystoscopy performed for cause after prostate brachytherapy
    Michael S Leapman
    Deane Prostate Health and Research Center, Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY
    Urology 83:1350-5. 2014
    ..To characterize cystoscopy findings performed for cause after prostate brachytherapy in men...
  26. doi request reprint Long-term potency preservation following brachytherapy for prostate cancer
    Kurt M Snyder
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 110:221-5. 2012
    ....
  27. ncbi request reprint Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 69:1472-7. 2007
    ..To investigate the biochemical control rate in patients undergoing permanent prostate brachytherapy as a function of the biologically effective dose (BED) and risk group...
  28. doi request reprint Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Oral Maxillofac Surg 67:159-61. 2009
    ..To determine whether any abnormality in serum bone markers is related to bisphosphonate-induced osteonecrosis of the jaw...
  29. ncbi request reprint Combined modality treatment in the management of high-risk prostate cancer
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, Box 1236, 1184 5th Avenue, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 59:1352-9. 2004
    ....
  30. ncbi request reprint Genetic predictors of adverse radiotherapy effects: the Gene-PARE project
    Alice Y Ho
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 65:646-55. 2006
    ..The purpose of the Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE) project is to help achieve this goal...
  31. doi request reprint Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up
    Michael Buckstein
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Urology 81:364-8. 2013
    ..To report the outcomes and late toxicities in younger patients with long-term follow-up treated with brachytherapy with or without external beam radiotherapy for prostate adenocarcinoma...
  32. doi request reprint Predictors of metastatic disease after prostate brachytherapy
    Kevin Forsythe
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 83:645-52. 2012
    ..To identify predictors of metastatic disease after brachytherapy treatment for prostate cancer...
  33. ncbi request reprint Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality
    Marisa A Kollmeier
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 57:645-53. 2003
    ..Patients treated during the first 6 years of the program were analyzed to determine the value of patient selection and implant quality on biochemical control...
  34. ncbi request reprint Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 66:389-94. 2006
    ....
  35. doi request reprint Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer
    Ryan J Burri
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 77:1338-44. 2010
    ..To describe long-term outcomes and toxicity after salvage brachytherapy (BT) for local failure after initial radiotherapy for prostate cancer...
  36. doi request reprint Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    Int J Radiat Oncol Biol Phys 76:355-60. 2010
    ..To determine factors that influence local control and systemic relapse in patients undergoing permanent prostate brachytherapy (PPB)...
  37. ncbi request reprint Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 2:17-25. 2003
    ..To compare the results of intraoperative dosimetry with those of CT-based postimplant dosimetry in patients undergoing prostate seed implantation...
  38. pmc Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases
    Charles C L Tong
    Department of Radiation Oncology, Mount Sinai Medical Center, New York, New York, United States of America
    PLoS ONE 7:e36979. 2012
    ..We tested the combination of sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant metastases...
  39. ncbi request reprint What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Brachytherapy 1:83-9. 2002
    ..To define the optimal dose for 125I prostate implants by correlating post implant CT dosimetry findings with urinary symptoms, biochemical failure, and posttreatment biopsies...
  40. ncbi request reprint Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Brachytherapy 1:2-10. 2002
    ..This article outlines treatment-related morbidity and PSA response to this regimen and analyzes the effect of escalating doses of brachytherapy...
  41. doi request reprint Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer
    Christopher A Peters
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 73:24-9. 2009
    ..To determine the impact familial prostate cancer has on prognosis in men treated with brachytherapy for clinically localized prostate cancer...
  42. ncbi request reprint Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer
    Alice Y Ho
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 6:38-43. 2007
    ..Dose-volume histogram (DVH) analysis of the SV was performed in patients with biopsy-positive SV who received implantation of the SV and prostate...
  43. ncbi request reprint Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy
    Jeremy G Price
    Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
    Int J Radiat Oncol Biol Phys 86:842-7. 2013
    ..We also report the patient and treatment factors predisposing to acute ≥ grade 2 proctitis...
  44. doi request reprint Haematuria after prostate brachytherapy
    Michael S Leapman
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    BJU Int 111:E319-24. 2013
    ..To characterize the incidence and clinical history of gross haematuria after prostate brachytherapy. To identify treatment risk factors for the development of gross haematuria in this setting...
  45. ncbi request reprint Patterns of local failure following prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    J Urol 177:1759-63; duscussion 1763-4. 2007
    ..We describe biopsy results in patients with prostate cancer treated with brachytherapy...
  46. ncbi request reprint Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 60:648-53. 2004
    ....
  47. ncbi request reprint Disease-specific survival following the brachytherapy management of prostate cancer
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai Hospital, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 64:810-6. 2006
    ..To determine disease-specific survival (DSS) and associated predictive factors after prostate brachytherapy...
  48. doi request reprint Prostate brachytherapy in men with gland volume of 100cc or greater: Technique, cancer control, and morbidity
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY10021, USA
    Brachytherapy 12:217-21. 2013
    ..To determine the outcomes of prostate seed implantation in men with prostate volume (PV) of 100cc or greater (PV100)...
  49. ncbi request reprint Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response
    Johnny Kao
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cancer 115:3571-80. 2009
    ..To determine the safety and maximum-tolerated dose of concurrent sunitinib and image-guided radiotherapy (IGRT) followed by maintenance sunitinib in oligometastastic patients...
  50. doi request reprint Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy
    Todd J Carpenter
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 10:261-8. 2011
    ..To evaluate the efficacy of multimodality therapy consisting of hormone therapy (HT), brachytherapy (BT), and external beam radiotherapy (EBRT) in extraprostatic prostate cancer and identify factors with predictive value...
  51. ncbi request reprint Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS
    Timothy M Zagar
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 6:26-33. 2007
    ..This study is to compare the Mount Sinai Erectile Function Score (MSEFS), our brachytherapy program's physician-assigned scale, with patients' independently completed International Index of Erectile Function-5 (IIEF-5)...
  52. ncbi request reprint Urinary symptom flare following I-125 prostate brachytherapy
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 56:1085-92. 2003
    ..We describe a late complication of I-125 prostate brachytherapy we have termed urinary symptom flare...
  53. ncbi request reprint Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 2:32-9. 2003
    ..This study prospectively assessed the long-term effects of (125)I prostate brachytherapy on urinary morbidity...
  54. doi request reprint There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy
    Amy N Solan
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Int J Radiat Oncol Biol Phys 73:1468-74. 2009
    ..We evaluated the relationship between the onset of erectile dysfunction and dose to the penile bulb and neurovascular bundles (NVBs) after real-time ultrasound-guided prostate brachytherapy...
  55. ncbi request reprint C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY 10029, USA
    BJU Int 95:961-2. 2005
    ....
  56. ncbi request reprint Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 56:448-53. 2003
    ..The impact of PSA bounce on PSA failure was also explored...
  57. ncbi request reprint Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai Medical Center, New York 10029, USA
    BJU Int 98:979-81. 2006
    ....
  58. pmc Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer
    Sarah L Kerns
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Radiother Oncol 107:372-6. 2013
    ..Rectal bleeding can occur following radiotherapy for prostate cancer and negatively impacts quality of life for cancer survivors. Treatment and clinical factors do not fully predict rectal bleeding, and genetic factors may be important...
  59. ncbi request reprint American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy
    Brian J Davis
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Brachytherapy 11:6-19. 2012
    ..To provide updated American Brachytherapy Society (ABS) guidelines for transrectal ultrasound-guided transperineal interstitial permanent prostate brachytherapy (PPB)...
  60. ncbi request reprint The role of hormonal therapy in prostate brachytherapy. Point
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY, USA
    Brachytherapy 2:1-2. 2003
  61. doi request reprint Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
    Nelson N Stone
    Departments of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 183:634-9. 2010
    ..We evaluated the effect of neoadjuvant hormonal therapy on urinary function in men with a prostate volume of 50 cc or greater undergoing prostate brachytherapy...
  62. ncbi request reprint Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai Medical Center, Bronx, New York, NY 10029, USA
    BJU Int 96:328-9. 2005
    ....
  63. ncbi request reprint Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 100:362-7. 2007
    ..To evaluate the effect of low-dose rate prostate brachytherapy on the sexual health of men with > or = 7 years of prospective evaluation and optimum sexual function before treatment...
  64. ncbi request reprint The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 177:925-8. 2007
    ..We describe the effects of prostate brachytherapy with or without hormonal therapy, or external beam irradiation on gland volume...
  65. ncbi request reprint Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease
    Christopher A Peters
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 66:424-9. 2006
    ..We report on the follow-up of 24 patients with a prior history of inflammatory bowel disease (IBD) treated with brachytherapy for early-stage prostate cancer...
  66. ncbi request reprint Prostate gland motion and deformation caused by needle placement during brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 1:154-60. 2002
    ..To determine the extent of edge and gland position changes caused by needle insertion in patients undergoing prostate brachytherapy...
  67. doi request reprint Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma
    Michael Buckstein
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 111:E43-7. 2013
    ..The study also shows that a significant amount of erectile dysfunction might be more age related than radiation induced...
  68. ncbi request reprint Biopsy and implantation of the seminal vesicles
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 11:334-40. 2012
    ..To describe the technique and outcomes of seminal vesicle biopsy (SVB) and permanent implantation in patients with T3b prostate cancer...
  69. ncbi request reprint Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York, USA
    Urol Oncol 21:101-4. 2003
    ..0, P = 0.14). Also, there is an association of APC mutations with thyroid cancer. In this study, we measured triiodothyronine (t3) levels in Ashkenazi Jewish prostate cancer patients, with and without the I1307K mutation of the APC gene...
  70. ncbi request reprint Influence of prostate volume on dosimetry results in real-time 125I seed implantation
    Lee K McNeely
    Department of Radiation Oncology, Boulder Community Hospital, Boulder, CO, USA
    Int J Radiat Oncol Biol Phys 58:292-9. 2004
    ..We determined whether the prostate size at implantation influenced the CT/US ratio results affecting postimplant dosimetry or predicted for D90 values <140 or >180 Gy in patients implanted with 125I in a community hospital setting...
  71. ncbi request reprint Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, 1 Gastave Levy Place, New York, NY 10029, USA
    Urol Clin North Am 30:351-62. 2003
    ..Well-controlled, randomized studies are needed. In the meantime, the clinician will have to rely on the available published data...
  72. ncbi request reprint Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy
    Steven Lehrer
    Department of Radiation Oncology and Urology, Mount Sinai Medical Center, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Urol 173:79-81. 2005
    ..In the current study we analyzed the relationship of prostate size and prostate specific antigen (PSA) failure in men undergoing brachytherapy for localized prostate cancer...
  73. ncbi request reprint Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 173:803-7. 2005
    ..We determined the 10-year biochemical and local control results for I prostate brachytherapy in men followed a minimum of 4 years...
  74. ncbi request reprint Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai School of Medicine and Veterans Affairs Medical Center, The Bronx, New York, USA
    J Urol 168:2431-3. 2002
    ..For this reason we assessed serum triiodothyronine levels in men with localized prostate cancer, benign prostatic hyperplasia (BPH) and controls in the same age group...
  75. ncbi request reprint Importance of post-implant dosimetry in permanent prostate brachytherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, Box 1236, 1184 5th Avenue, New York, NY 10025, USA
    Eur Urol 41:434-9. 2002
    ..The technique, results and correlation with clinical outcomes will be presented...
  76. ncbi request reprint High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer: The case for low-dose-rate monotherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 5:5-6; discussion 8. 2006
  77. ncbi request reprint Brachytherapy for the treatment of prostate cancer
    Jamie A Cesaretti
    Department of Radiation Oncology, The Mount Sinai School of Medicine, James J Peters VA Hospital, New York, NY, USA
    Cancer J 13:302-12. 2007
    ....
  78. ncbi request reprint Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer
    Steven Lehrer
    Department of Radiation Oncology and Urology, Mount Sinai School of Medicine, New York, NY, USA
    Urol Oncol 7:73-6. 2002
    ..We assessed the relationship of American Urological Association (AUA) urinary symptom score and tumor stage in men treated for localized prostate cancer...
  79. ncbi request reprint Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States
    Steven J Frank
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Brachytherapy 6:2-8. 2007
    ..This study is aimed at understanding and defining the current patterns of care with respect to prostate brachytherapy for patients with intermediate-risk localized disease in the combined academic and community setting...
  80. ncbi request reprint Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:389-91. 2008
    ..This anatomic concentration of bisphosphonates might cause bisphosphonate-osteonecrosis to be manifested exclusively in the jaws and is consistent with our finding of normal serum bone markers in ONJ patients...
  81. ncbi request reprint Increased serum insulin associated with increased risk of prostate cancer recurrence
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Prostate 50:1-3. 2002
    ....
  82. ncbi request reprint ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects
    Christopher M Iannuzzi
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 52:606-13. 2002
    ..This study attempted to determine whether breast cancer patients who develop severe radiotherapy (RT)-induced effects are more likely to possess ATM mutations than patients who display normal radiation responses...
  83. ncbi request reprint Permanent seed implantation for localized adenocarcinoma of the prostate
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA
    Curr Urol Rep 3:201-6. 2002
    ..Advances in technology, such as intraoperative dosimetry, will continue to make brachytherapy an attractive treatment option for men with localized prostate cancer...
  84. ncbi request reprint Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    Urology 66:119-23. 2005
    ..All have been associated with some degree of pulmonary seed migration, and no studies have clearly investigated a means of decreasing this problem...